Effect of CYP2C8 inhibition by trimethoprim on the pharmacokinetics of rosiglitazone.

被引：0
|
作者：
Hruska, MW [1 ]
Amico, JA [1 ]
Frye, RF [1 ]
机构：
[1] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2003年 / 43卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
92
引用
收藏
页码：1036 / 1036
页数：1
相关论文
共 50 条
  • [41] In Silico Prediction of CYP2C8 Inhibition with Machine-Learning Methods
    Zhang, Xiaoxiao
    Zhao, Piaopiao
    Wang, Zhiyuan
    Xu, Xuan
    Liu, Guixia
    Tang, Yun
    Li, Weihua
    CHEMICAL RESEARCH IN TOXICOLOGY, 2021, 34 (08) : 1850 - 1859
  • [42] CYP2C8 polymorphism among the Portuguese
    Cavaco, I
    Piedade, R
    Gil, JP
    Ribeiro, V
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2006, 44 (02) : 168 - 170
  • [43] Influence of CYP2C8☆2 on the Pharmacokinetics of Pioglitazone in Healthy African-American Volunteers
    Aquilante, Christina L.
    Wempe, Michael F.
    Spencer, Samantha H.
    Kosmiski, Lisa A.
    Predhomme, Julie A.
    Sidhom, Maha S.
    PHARMACOTHERAPY, 2013, 33 (09): : 1000 - 1007
  • [44] Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human
    Haraya, Kenta
    Kato, Motohiro
    Chiba, Koji
    Sugiyama, Yuichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (06) : 277 - 285
  • [45] CYP2C8 and antimalaria drug efficacy
    Gill, J. P.
    Berglund, E. Gil
    PHARMACOGENOMICS, 2007, 8 (02) : 187 - 198
  • [46] Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic DrugsClinical Relevance
    Julia Kirchheiner
    Ivar Roots
    Mark Goldammer
    Bernd Rosenkranz
    Jürgen Brockmöller
    Clinical Pharmacokinetics, 2005, 44 : 1209 - 1225
  • [47] Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil
    Katsumi Iga
    Akiko Kiriyama
    Clinical Pharmacokinetics, 2024, 63 : 43 - 56
  • [48] Evaluation of the Relationship between Sex, Polymorphisms in CYP2C8 and CYP2C9, and Pharmacokinetics of Angiotensin Receptor Blockers
    Cabaleiro, Teresa
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Prieto-Perez, Rocio
    Wojnicz, Aneta
    Lopez-Rodriguez, Rosario
    Novalbos, Jesus
    Abad-Santos, Francisco
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (01) : 224 - 229
  • [49] The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose:: Evidence for mechanism-based inhibition of CYP2C8 in vivo
    Tornio, A.
    Niemi, M.
    Neuvonen, M.
    Laitila, J.
    Kalliokoski, A.
    Neuvonen, P. J.
    Backman, J. T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) : 403 - 411
  • [50] Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil
    Iga, Katsumi
    Kiriyama, Akiko
    CLINICAL PHARMACOKINETICS, 2024, 63 (01) : 43 - 56
12345